Incyte (INCY)
(Delayed Data from NSDQ)
$65.74 USD
-1.08 (-1.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $65.63 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.74 USD
-1.08 (-1.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $65.63 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
by Zacks Equity Research
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
New Strong Sell Stocks for June 16th
by Zacks Equity Research
ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte
by Zacks Equity Research
Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog.
Top Analyst Reports for Fomento Economico Mexicano, NextEra Energy & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Charter Communications, Inc. (CHTR).
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
by Zacks Equity Research
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
by Ekta Bagri
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Molina Healthcare (MOH) in Q1 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
by Zacks Equity Research
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
by Zacks Equity Research
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks
by Zacks Equity Research
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
by Zacks Equity Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
by Zacks Equity Research
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
Company News for Mar 27, 2023
by Zacks Equity Research
Companies in The News Are: SQ,INCY,JPM,WFC
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
by Zacks Equity Research
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
by Zacks Equity Research
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
by Zacks Equity Research
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
by Zacks Equity Research
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.
Incyte (INCY) Down 8.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.